Korea Arlico Pharm Co.,Ltd. (260660.KQ)
- Previous Close
4,465.00 - Open
4,535.00 - Bid 4,360.00 x --
- Ask 4,420.00 x --
- Day's Range
4,350.00 - 4,535.00 - 52 Week Range
3,070.00 - 6,130.00 - Volume
138,943 - Avg. Volume
1,921,190 - Market Cap (intraday)
65.984B - Beta (5Y Monthly) 0.77
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date --
- Forward Dividend & Yield 75.00 (1.68%)
- Ex-Dividend Date Dec 27, 2024
- 1y Target Est
--
Korea Arlico Pharm Co.,Ltd. engages in the researches and develops, produces, and sells medicines in South Korea. It offers ETC, OTC, medical device, and other products; and active ingredients. The company provides products in the areas of circulatory system, anti-platelet, dementia, muscle relaxants, diabetes, NSAIDS and analgesics, ointment/cream, respiratory system, gastrointestinal, metabolic disease, antihistamines, anti-virus, genitourinary, alopecia, psychoneurotic, CNS, anthelmintics, and hypnotic diseases. Korea Arlico Pharm Co.,Ltd. was founded in 1992 and is headquartered in Seoul, South Korea.
www.arlico.co.kr--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 260660.KQ
View MorePerformance Overview: 260660.KQ
Trailing total returns as of 4/23/2025, which may include dividends or other distributions. Benchmark is KOSPI Composite Index (^KS11) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 260660.KQ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 260660.KQ
View MoreValuation Measures
Market Cap
67.03B
Enterprise Value
98.30B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.35
Price/Book (mrq)
0.84
Enterprise Value/Revenue
0.52
Enterprise Value/EBITDA
38.61
Financial Highlights
Profitability and Income Statement
Profit Margin
-2.81%
Return on Assets (ttm)
-1.87%
Return on Equity (ttm)
-6.35%
Revenue (ttm)
190.44B
Net Income Avi to Common (ttm)
-5.36B
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
19.19B
Total Debt/Equity (mrq)
63.32%
Levered Free Cash Flow (ttm)
-14.24B